• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[氯喹和羟氯喹:重要治疗药物的副作用概况]

[Chloroquine and hydroxychloroquine: side effect profile of important therapeutic drugs].

作者信息

Ochsendorf F R, Runne U

机构信息

Zentrum der Dermatologie und Venerologie, J.W. Goethe-Universität, Frankfurt/M.

出版信息

Hautarzt. 1991 Mar;42(3):140-6.

PMID:2055762
Abstract

Precise knowledge of the undesirable effects of chloroquine and hydroxychloroquine allows better exploitation of their therapeutic effects. Retinopathy can be avoided by observing a maximum daily dosage of 3.5-4 mg/kg ideal body weight for chloroquine and 6-6.5 mg/kg for hydroxychloroquine. In this way, both can be used for long-term therapy. The pharmacokinetics of chloroquine (storage in deep compartments with long plasma half-life) means that it can cumulate, especially with higher dosages and in the presence of renal or hepatic insufficiency. A high plasma concentration reinforces the side-effects without reinforcing the therapeutic effects. Besides subjective symptoms (e.g. anorexia, diarrhoea, nausea), the following undesirable reactions are significant. On the skin exanthema, hyperpigmentation and photodynamic reactions can develop. The hair can become white in blonde and red-haired men. In the eye, chloroquine deposits in the cornea and disturbances of accommodation can occur, besides retinopathy. Neuromyopathy and central nervous system disturbances (e.g. psychosis) are rare, as is impairment of auditory function or blood cells. During pregnancy there is a risk of potential fetal damage (hearing loss, abortion). An acute overdose is extremely dangerous: the lethal dose is 1 g for children and 4 g for adults. As death occurs rapidly, chloroquine has to be stored where it is absolutely inaccessible to children.

摘要

准确了解氯喹和羟氯喹的不良反应有助于更好地发挥它们的治疗作用。通过观察氯喹每日最大剂量为理想体重3.5 - 4毫克/千克,羟氯喹为6 - 6.5毫克/千克,可避免视网膜病变。这样,两者都可用于长期治疗。氯喹的药代动力学(储存在深部隔室,血浆半衰期长)意味着它会蓄积,尤其是在剂量较高以及存在肾或肝功能不全时。高血浆浓度会增强副作用,但不会增强治疗效果。除了主观症状(如厌食、腹泻、恶心)外,以下不良反应较为显著。在皮肤上可出现皮疹、色素沉着和光动力反应。金发和红发男性的头发可能变白。在眼部,除视网膜病变外,氯喹还可沉积在角膜并出现调节障碍。神经肌肉病变和中枢神经系统紊乱(如精神病)较为罕见,听觉功能或血细胞受损也很少见。怀孕期间存在潜在胎儿损伤(听力丧失、流产)的风险。急性过量极其危险:儿童致死剂量为1克,成人为4克。由于死亡迅速发生,氯喹必须储存在儿童绝对无法触及的地方。

相似文献

1
[Chloroquine and hydroxychloroquine: side effect profile of important therapeutic drugs].[氯喹和羟氯喹:重要治疗药物的副作用概况]
Hautarzt. 1991 Mar;42(3):140-6.
2
[Chloroquine retinopathy: preventable by monitoring the maximum daily dose].[氯喹视网膜病变:通过监测每日最大剂量可预防]
Hautarzt. 1988 Jun;39(6):341-2.
3
Dose relationships in patients with early chloroquine retinopathy.早期氯喹视网膜病变患者的剂量关系。
J Rheumatol. 1987 Jun;14(3):472-5.
4
[Complications in chloroquin therapy].
Acta Med Austriaca. 1975;2(4):116-21.
5
[Chloroquine retinopathy: avoidable by individualized daily dosing].[氯喹视网膜病变:可通过个体化每日给药避免]
Dtsch Med Wochenschr. 1993 Dec 23;118(51-52):1895-8. doi: 10.1055/s-2008-1059529.
6
Hydroxychloroquine and chloroquine: assessing the risk of retinal toxicity.羟氯喹和氯喹:评估视网膜毒性风险。
J Am Optom Assoc. 1993 Nov;64(11):787-97.
7
An ophthalmological view on the efficacy and safety of chloroquine versus hydroxychloroquine.氯喹与羟氯喹疗效及安全性的眼科视角
J Rheumatol. 1999 Sep;26(9):1866-8.
8
Pharmacokinetics of hydroxychloroquine and chloroquine during treatment of rheumatic diseases.羟氯喹和氯喹在风湿性疾病治疗中的药代动力学
Lupus. 1996 Jun;5 Suppl 1:S11-5.
9
The blood-retinal barrier in chloroquine retinopathy.氯喹视网膜病变中的血视网膜屏障
Invest Ophthalmol Vis Sci. 1989 Aug;30(8):1726-31.
10
[Synthetic antimalarials].[合成抗疟药]
Ann Dermatol Venereol. 2005 Aug-Sep;132(8-9 Pt 1):665-74. doi: 10.1016/s0151-9638(05)79414-x.

引用本文的文献

1
Prophylactic use of hydroxychloroquine (HCQS) in COVID-19: A questionnaire-based study in health care professionals.在 COVID-19 中预防性使用羟氯喹(HCQS):一项针对医疗保健专业人员的基于问卷的研究。
Ann Afr Med. 2022 Apr-Jun;21(2):113-117. doi: 10.4103/aam.aam_82_20.
2
COVID-19 Treatments Sold Online Without Prescription Requirements in the United States: Cross-sectional Study Evaluating Availability, Safety and Marketing of Medications.美国未经处方要求在网上销售的 COVID-19 治疗药物:评估药物可获得性、安全性和营销情况的横断面研究。
J Med Internet Res. 2022 Feb 16;24(2):e27704. doi: 10.2196/27704.
3
Risk versus Benefit of Using Hydroxychloroquine to Treat Patients with COVID-19.
使用羟氯喹治疗2019冠状病毒病患者的风险与益处
Can J Infect Dis Med Microbiol. 2021 Sep 15;2021:5942366. doi: 10.1155/2021/5942366. eCollection 2021.
4
Knowledge, Attitude, and Practice of the Lebanese Community Toward COVID-19.黎巴嫩社区对新冠病毒的认知、态度和行为
Front Med (Lausanne). 2020 Aug 18;7:542. doi: 10.3389/fmed.2020.00542. eCollection 2020.
5
Psychiatric Morbidities among COVID-19 Survivors.新冠病毒疾病幸存者中的精神疾病
South Med J. 2020 Sep;113(9):466-467. doi: 10.14423/SMJ.0000000000001146.
6
Evaluation of Current Therapies for COVID-19 Treatment.新冠病毒病治疗现有疗法的评估
Microorganisms. 2020 Jul 22;8(8):1097. doi: 10.3390/microorganisms8081097.
7
[37-year-old male with confluent papules and arcuate erythematosquamous plaques on the upper trunk and arms : Preparation for the specialist examination: part 22].[37岁男性,上躯干和手臂出现融合性丘疹及弧形红斑鳞屑性斑块:专科检查准备:第22部分]
Hautarzt. 2018 Nov;69(Suppl 2):173-176. doi: 10.1007/s00105-018-4297-0.
8
Nanodiamond autophagy inhibitor allosterically improves the arsenical-based therapy of solid tumors.纳米金刚石自噬抑制剂变构改善基于砷剂的实体瘤治疗效果。
Nat Commun. 2018 Oct 19;9(1):4347. doi: 10.1038/s41467-018-06749-2.
9
NF-κB Signaling Activation Induced by Chloroquine Requires Autophagosome, p62 Protein, and c-Jun N-terminal Kinase (JNK) Signaling and Promotes Tumor Cell Resistance.氯喹诱导的NF-κB信号激活需要自噬体、p62蛋白和c-Jun氨基末端激酶(JNK)信号,并促进肿瘤细胞耐药。
J Biol Chem. 2017 Feb 24;292(8):3379-3388. doi: 10.1074/jbc.M116.756536. Epub 2017 Jan 12.
10
Use of antimalarials in dermatology.抗疟药物在皮肤科的应用。
J Dtsch Dermatol Ges. 2010 Oct;8(10):829-44; quiz 845. doi: 10.1111/j.1610-0387.2010.07490.x. Epub 2010 Jul 29.